2025-11-15 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided.

## JNJ Stock Analysis (November 15, 2025)

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** JNJ
*   **Company:** Johnson & Johnson - A global healthcare company focused on pharmaceuticals, medical devices, and consumer health products.
*   **JNJ Cumulative Return:** 50.49%
*   **VOO Cumulative Return:** 98.45%
*   **Underperformance:** JNJ has significantly underperformed the S&P 500 (VOO) over the period.
*   **Deviation:**
    *   Current Deviation: -56.6%
    *   Deviation Range: Max 16.6%, Min -65.5%
    *   Relative Deviation: 10.8% (Indicates JNJ's underperformance is near the lower end of its historical range compared to VOO.)

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2015-2017  | 26.0% | 66.8% | -2.0%  | 0.0  | 336.6  |
| 2016-2018  | 14.0% | 10.7% | -1.0%  | 0.1  | 310.9  |
| 2017-2019  | 20.0% | 71.5% | -2.0%  | 0.4  | 351.4  |
| 2018-2020  | 19.0% | 79.2% | -4.0%  | 0.4  | 379.2  |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5  | 412.2  |
| 2020-2022  | 8.0%  | 79.6% | 9.0%   | 0.4  | 425.6  |
| 2021-2023  | -19.0% | 79.6% | -21.0% | 0.3  | 377.6  |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3  | 348.4  |
| 2023-2025  | 22.0% | 79.6% | -41.0% | 0.1  | 472.1  |

**Analysis:**

*   **Alpha:** JNJ has consistently negative alpha in most periods, indicating underperformance compared to its expected return based on its beta.  The recent periods show significant negative alpha, meaning JNJ is significantly underperforming relative to the market.
*   **Beta:** Beta values are relatively low (around 0.1-0.5), suggesting JNJ is less volatile than the overall market.
*   **CAGR:**  CAGR (Compound Annual Growth Rate) has varied significantly over the years, with recent periods showing negative growth.
*   **MDD:**  Maximum Drawdown is high in most periods, indicating significant potential losses during market downturns.

### 2. Recent Stock Price Movement

*   **Current Price:** 195.93
*   **Previous Close:** 195.25
*   **Change:** 0.35 (Slight increase, reflecting a minor positive movement.)
*   **5-day Moving Average:** 193.562
*   **20-day Moving Average:** 190.0503
*   **60-day Moving Average:** 184.4188

**Analysis:**

JNJ's current price is above its 5, 20, and 60-day moving averages, suggesting a short-term uptrend. The recent slight price increase of 0.35 further supports this observation, indicating positive market momentum.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 62.31 (RSI is above 50, it indicates that the stock is experiencing bullish momentum)
*   **PPO:** 0.3072
*   **Hybrid Signal:** "Cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90)" (Strong buy signal suggesting full investment based on the safety and MRI)
*   **20-day Relative Deviation Change:** +5.9 (Short-term increase in relative deviation, suggesting a recent uptick compared to its historical performance.)
*   **Expected Return:** -179.8% (Significantly negative, indicating substantial underperformance relative to the S&P 500 in the long term.)

**Analysis:**

*   The MRI suggests a medium level of risk, making JNJ a moderately attractive investment based on market conditions.
*   RSI above 50 indicates bullish momentum.
*   The hybrid signal indicates a strong buy, but the extremely negative expected return suggests caution. The negative expected return raises serious concerns about long-term investment potential compared to the S&P 500.

### 4. Recent News & Analyst Opinions

**Recent News:**

*   Mixed headlines: Some articles highlight sector weaknesses in healthcare, while others focus on broader market trends or individual company (Pfizer) situations.
*   Specifically, the Bristol Myers Squibb news could potentially impact the overall sentiment towards the pharmaceutical sector, including JNJ.

**Analyst Opinions:**

*   **Consensus:** Buy (Mean of 2.16 suggests a general "Buy" recommendation).
*   **Target Price:** Average target of $200.82 suggests potential upside from the current price.
*   **Recent Rating Changes:** No information provided on recent rating changes.

**Analysis:**

Analysts are generally positive on JNJ, with a consensus "Buy" rating and a target price above the current market price. However, the recent news headlines introduce some uncertainty, particularly within the healthcare sector.

### 5. & 6. Earnings and Financial Information:

**Earnings Data:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

**Analysis:**

*   EPS (Earnings Per Share) has fluctuated.
*   Revenue shows some variability, but generally remains in the $21.89B to $23.99B range.

**Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue      | Profit Margin |
|--------------|--------------|---------------|
| 2025-09-30   | $23.99B      | 69.56%        |
| 2025-06-30   | $23.74B      | 67.87%        |
| 2025-03-31   | $21.89B      | 66.40%        |
| 2024-12-31   | $22.52B      | 68.35%        |
| 2024-09-30   | $22.47B      | 69.01%        |

Capital and Profitability:

| Quarter      | Equity      | ROE    |
|--------------|-------------|--------|
| 2025-09-30   | $79.28B     | 6.50%  |
| 2025-06-30   | $78.47B     | 7.06%  |
| 2025-03-31   | $78.11B     | 14.08% |
| 2024-12-31   | $71.49B     | 4.80%  |
| 2024-09-30   | $70.16B     | 3.84%  |

**Analysis:**

*   **Revenue:** Generally stable revenue figures around $22-24 billion per quarter.
*   **Profit Margin:** Consistently high-profit margins, generally around 67-70%, indicating strong profitability.
*   **Equity:** Increasing equity suggests growth in the company's net assets.
*   **ROE:** ROE (Return on Equity) varies, with a notable spike in Q1 2025, indicating changes in profitability relative to equity.

### 7. Overall Assessment

**Summary:**

JNJ shows a mixed picture. While it's a stable, large-cap company with a history of profitability, its recent performance has significantly lagged the S&P 500.

**Key Points:**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 (VOO) in recent years.
*   **Technicals:** Short-term uptrend suggested by moving averages.
*   **Risk:** Medium risk based on MRI.
*   **Analyst Sentiment:** Generally positive ("Buy" ratings) with a potential upside to the average target price.
*   **Financials:** Stable revenue, high-profit margins, and growing equity.
*    **Expected Return:** Highly negative expected return raises significant concerns.

**Conclusion:**

Despite positive analyst ratings and stable financial metrics, the significant underperformance compared to the S&P 500 and the negative expected return raise concerns about the long-term investment potential of JNJ. Investors should carefully weigh these factors against the company's inherent stability and high-profit margins before making any investment decisions. The analyst buy recommendation is conflicted with the underperformance and negative expected return, indicating potential risks in the recommendation.
